
|Videos|June 30, 2021
The Future of Pharmaceuticals and the FDA Pipeline
Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, discusses upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.
Advertisement
Pharmacy Times spoke with Chad Landmon, attorney and chair of Axinn’s Intellectual Property and FDA Practice Groups, about key events in the FDA pipeline, such as Emergency Use Authorizations during COVID-19 and the future of narrowed approvals.
Landmon went into further detail on upcoming clinical trials on COVID-19 booster shots, the possibility of cancer vaccines, and the future of pharmaceuticals and FDA approvals.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
2
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
3
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
4
Building a Pharmacist-Led Furoscix Workflow From Scratch
5


































































































